Research article · 26 Jul 2016
Conference abstractPublished 23 Sep 2013
Integrated strategy for biosimilar development: A multidisciplinary approach for risk reduction
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Many companies have recently entered the biosimilar space. After the initial excitement, reality set in resulting in a number of attritions. Some could have been avoided if companies had invested in understanding the dynamics and challenges of developing and commercializing a biosimilar. This includes the impact of commercial issues on the development strategy, considerations which even impact the choice of biosimilar target. Often companies focus on developing a data package to address regulatory requirements and don?t ask the pivotal question, what is needed to ensure commercial success with the multitude of target audiences: payors, physicians, patients, and the threat of large biotech counterstrategies. Competition for patient recruitment is also overlooked. The CMC challenge is also great. The quality target product profile (QTPP) based on data collected on the reference product is required at the onset of process development. Thus, the analytical burden is higher and occurs earlier compared to developing a new biologic. In addition, many of the attractive candidates are glycosylated and demonstration of biosimilarity includes thorough carbohydrate analysis. Glycosylation is defined by the cells and sensitive to changes in process conditions. Pursuing cost reduction, biosimilar manufacturers are tempted by novel expression systems which may introduce atypical glycosylation and higher variability as compared to the reference product. Thus, the understanding of the glycobiology of expression systems is critical in pursuing this endeavor. Given the number and intricate correlation of the challenges involved, it is critical to take an integrated approach to the development of biosimilars.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 24 Oct 2018
How to start a Biosimilar development: A risk based approach
Conference abstract · 27 Oct 2014
Risk assessment: A pragmatic approach to develop biosimilars
Editorial · 2021
The Development of Disaster Risk Reduction Strategies and Techniques
Case report · 15 May 2019
Effective Reduction of Mental Trauma with a Multidisciplinary Approach to Treatment of Dental Trauma
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Adriana E. Manzi”

